Adverse effects (participant interviews) · adults and children with cystic fibrosis
1 finding from 1 review
Total gastrointestinal symptom scores (participant‐reported symptom scores from 20 to 100) · adults and children with cystic fibrosis
1 finding from 1 review
Hospitalisation (any cause) · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation for DIOS · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tolerability · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: relative change from baseline · adults and children with CF
1 finding from 1 review
Time to next exacerbation · adults and children with CF
1 finding from 1 review
Participants hospitalised for respiratory exacerbation · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in participants hospitalised for respiratory exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis
1 finding from 1 review
Diarrhoea · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes adverse events: diarrhoea compared with placebo (very low certainty).
1 finding from 1 review
FEV1 % predicted · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FEV1 % predicted compared with placebo (very low certainty).
1 finding from 1 review
FVC · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FVC % predicted compared with placebo (very low certainty).
1 finding from 1 review
Z score BMI · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes growth and nutrition: BMI SD score compared with placebo (very low certainty).
1 finding from 1 review
Biochemical markers of essential fatty acid status: EPA and DHA % content of neutrophil membrane · adults and children with cystic fibrosis
1 finding from 1 review
Detumescence · men and boys with SCD and stuttering priapism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Effect on later sexual function · men and boys with SCD and stuttering priapism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other untoward side effects of treatment · men and boys with SCD and stuttering priapism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found